Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

December 2017

New Prior Authorization Policy for Radicava


Harvard Pilgrim has developed a prior authorization policy for the new-to-market drug Radicava. The FDA approved Radicava (edaravone) in May 2017 to treat patients with amyotrophic lateral sclerosis (ALS). Effective for dates of service beginning Dec. 15, 2017, Harvard Pilgrim will cover Radicava for the treatment of ALS with prior authorization, when the criteria outlined in the new policy have been met.

As a reminder, CVS Health–NovoLogix oversees our prior authorization program for medical drugs to optimize treatment outcomes and promote the safe and cost-effective use of these medications. To request authorization for Radicava, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete information, please refer to our new Radicava Medical Review Criteria.

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

New Monthly Publication Date for Network Matters

New Policy: Maximum Dosages for Medical Drugs

Webinar for Genetic Testing Authorization for Medicare Members

New Medicare Beneficiary Identifier Coming in 2018

Methadone Maintenance Benefit Change in Massachusetts

Study Suggests Breastfed Babies Are Less Likely to Have Eczema as Teens

CLINICIAN CORNER

Changes to Premium Formulary for 2018

New Prior Authorization Policy for Radicava

Keytruda and Opdivo Prior Authorization Policies Updated

Depression Screening and Treatment

OFFICE ASSISTANT

Keep Panel Status and Demographic Information Up to Date

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Senior Vice President, Network Strategy

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator